Apogee Therapeutics Inc
NASDAQ:APGE
Intrinsic Value
Apogee Therapeutics Inc is a US-based company operating in Biotechnology industry. [ Read More ]
The intrinsic value of one APGE stock under the Base Case scenario is 7.02 USD. Compared to the current market price of 51.17 USD, Apogee Therapeutics Inc is Overvalued by 86%.
Valuation Backtest
Apogee Therapeutics Inc
Run backtest to discover the historical profit from buying and selling APGE stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Apogee Therapeutics Inc
Current Assets | 398.4m |
Cash & Short-Term Investments | 395.5m |
Other Current Assets | 3m |
Non-Current Assets | 3m |
PP&E | 2.6m |
Other Non-Current Assets | 401k |
Current Liabilities | 20.6m |
Accounts Payable | 2.1m |
Accrued Liabilities | 18.4m |
Non-Current Liabilities | 933k |
Other Non-Current Liabilities | 933k |
Earnings Waterfall
Apogee Therapeutics Inc
Revenue
|
0
USD
|
Operating Expenses
|
-93m
USD
|
Operating Income
|
-93m
USD
|
Other Expenses
|
9m
USD
|
Net Income
|
-84m
USD
|
Free Cash Flow Analysis
Apogee Therapeutics Inc
APGE Profitability Score
Profitability Due Diligence
Apogee Therapeutics Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
Apogee Therapeutics Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
APGE Solvency Score
Solvency Due Diligence
Apogee Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Apogee Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
APGE Price Targets Summary
Apogee Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for APGE is 87.52 USD with a low forecast of 75.75 USD and a high forecast of 99.75 USD.
Ownership
APGE Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
APGE Price
Apogee Therapeutics Inc
Average Annual Return |
N/A
|
Standard Deviation of Annual Returns |
N/A
|
Max Drawdown | -39% |
Market Capitalization | 2.9B USD |
Shares Outstanding | 56 367 800 |
Percentage of Shares Shorted | 12.69% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Apogee Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Waltham, Massachusetts and currently employs 27,000 full-time employees. The company went IPO on 2023-07-14. Apogee Therapeutics, Inc. is a biotechnology company. The firm is engaged in developing differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with high unmet need. Its advanced programs are APG777 and APG808, which are developed for the treatment of AD and COPD. APG777 is a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) targeting IL-13. APG808 is an SQ extended half-life mAb targeting IL-4Rα. Its earlier-stage programs, APG990 and APG222, utilize advanced antibody engineering to target OX40L and both IL-13 and OX40L, which are developed for the treatment of AD. APG222 is one or more extended half-life SQ antibodies targeting both IL-13 and OX40L, which has the potential to improve outcomes in AD.
Contact
IPO
Employees
Officers
The intrinsic value of one APGE stock under the Base Case scenario is 7.02 USD.
Compared to the current market price of 51.17 USD, Apogee Therapeutics Inc is Overvalued by 86%.